Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Navicixizumab
Trade Name
Synonyms OMP-305B83|OMP 305B83|OMP305B83
Drug Descriptions

Navicixizumab (OMP-305B83) is a bispecific antibody that binds both DLL4 and VEGF, which inhibits NOTCH and VEGFR signaling and may prevent angiogenesis and tumor growth (PMID: 30229512).

DrugClasses DLL4 Antibody 7 VEGF Antibody 10
CAS Registry Number 1638338-43-8
NCIT ID C119620


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Fluorouracil + Irinotecan + Leucovorin + Navicixizumab Fluorouracil Irinotecan Leucovorin Navicixizumab 0 1
Irinotecan + Navicixizumab Irinotecan Navicixizumab 0 1
Navicixizumab Navicixizumab 0 2
Navicixizumab + Paclitaxel Navicixizumab Paclitaxel 0 2

Additional content available in CKB BOOST